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Abstract
Objectives There is emerging evidence for a genetic basis
of patient-reported quality-of-life (QOL) outcomes that can
ultimately be incorporated into clinical research and prac-
tice. Objectives are (1) to provide arguments for the
timeliness of investigating the genetic basis of QOL given
the scientific advances in genetics and patient-reported
QOL research; (2) to describe the clinical implications of
such investigations; (3) to present a theoretical foundation
for investigating the genetic underpinnings of QOL; and
(4) to describe a series of papers resulting from the
GENEQOL Consortium that was established to move this
work forward.
Methods Discussion of scientific advances based on rel-
evant literature.
Results In genetics, technological advances allow for
increases in speed and efficiency and decreases in costs in
exploring the genetic underpinnings of disease processes,
drug metabolism, treatment response, and survival. In
patient-based research, advances yield empirically based
and stringent approaches to measurement that are scien-
tifically robust. Insights into the genetic basis of QOL will
ultimately allow early identification of patients susceptible
to QOL deficits and to target care. The Wilson and Cleary
model for patient-reported outcomes was refined by
incorporating the genetic underpinnings of QOL.
Conclusions This series of papers provides a path for
QOL and genetics researchers to work together to move
this field forward and to unravel the intricate interplay of
the genetic underpinnings of patient-reported QOL out-
comes. The ultimate result will be a greater understanding
of the process relating disease, patient, and doctor that will
have the potential to lead to improved survival, QOL, and
health services delivery.
Keywords Quality of life  Patient-reported outcomes 
Genetic variables  Theory  Clinical implications
Introduction
There is emerging evidence for a genetic basis of patient-
reported quality-of-life (QOL) outcomes that can be
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incorporated into clinical research and practice. In this
paper, we provide arguments to indicate that scientific
advances in genetics and patient-reported QOL research
make this a timely endeavor. We further describe the clin-
ical implications of this work and how this has the potential
to expand and improve the quality of health care delivery.
We also present a theoretical foundation for investigating
the genetic underpinnings of patient-reported QOL, which
delineates the hypothetical interconnections among the
various components from the molecular level to clinical
outcomes. Finally, we describe a series of papers resulting
from the international and interdisciplinary GENEQOL
Consortium that purports to investigate potential biological
pathways, genes, and genetic variants involved in QOL.
Scientific imperatives
The fields of genetics and patient-reported QOL research
have experienced significant advances in recent years.
Genetic research has burgeoned despite the myriad of
genetic variables. Technical advancements allow for
increases in speed and efficiency and reduced costs of
genetics research, such as high-throughput sequencing and
new generations of micro-array techniques (see the
Appendix that includes a glossary of genetic terms). The
rapid expansion of the exploration of the human genome
involving genome-wide association studies (GWAS) has
made it possible to identify a large number of robust
associations between specific chromosomal loci and com-
plex human diseases, such as type 2 diabetes and rheu-
matoid arthritis [1]. Since 2007, GWAS have identified
more than 250 genetic loci of common genetic variants
involved in these and other common diseases. According to
Hirschhorn [2; page 1699], this ‘explosion represents one
of the most prolific periods of discovery in human genet-
ics’. Identifying genetic markers that are risk factors for
disease and delineating the genetic underpinnings of dis-
ease processes, drug metabolism, treatment response, and
survival have a central place on the research agenda. Initial
explorations into gene-environment interactions have
caused genetic researchers to think beyond a strictly
molecular level to include interactions at the level of the
organism and the world around the organism [3].
Before we describe the scientific advances of QOL
research, we will first clarify the key components. Since the
focus of this paper is on QOL, we will either refer to QOL
when we mean it to be applicable to individuals in general,
or to the newer term patient-reported (as synonymous to
health-related) QOL when we mean the narrower concept
applicable to patients. We will use the more general term
patient-reported outcomes (PRO) when we refer to any
report coming directly from patients [4].
Patient-based QOL research has progressed in parallel to
genetics research. A number of patient-reported QOL
measures are available that have the requisite measurement
properties for routine use in clinical research. Clearly,
PRO-related research differs from genetic research in the
source of information. However, the two research fields
have more in common than meets the eye. For example,
both fields face challenges caused by multiplicity of out-
comes, power considerations, missing data, and validation
issues. It should also be noted that all measures are asso-
ciated with error, whether they are obtained by self-report,
physical examination, or in the laboratory [5]. Therefore,
there is no inherent difference in variability and/or mea-
surement error derived from PRO-based science than from
test tube-based science. For example, it is well known but
often ignored that there are multiple sources of variability
and error in genotyping an individual [6, 7].
There are also detailed guidelines [8–10] and checklists
[11] on how to conduct scientifically sound patient-repor-
ted QOL research and to circumvent previously identified
barriers to implementation. More specifically, it is now
well established that existing patient-reported QOL mea-
sures are as reliable as most other clinical outcomes,
including clinician-rated outcomes of patient well-being
and laboratory data [5]. This finding holds particularly at
the group level. Furthermore, the guidelines that are
available have proven to be useful: the quality of trial-
based QOL data has improved over time [12]. Moreover,
one of the most provocative findings in QOL research is
that patient-reported assessments do not only have unique
prognostic value but are in some cases even superior to
clinician-based evaluations and biomedical assessments for
predicting survival in general populations [13] and chron-
ically ill patients [14–17]. Finally, clinical significance of
patient-reported QOL data can be established, given the
currently available guidelines [18–20]. In summary, these
advances establish that patient-reported QOL outcomes,
built on empirically based and stringent approaches to
measurement, are scientifically robust and do not need to
be viewed nor handled differently than any other parameter
in medical research [21].
Investigations of the genetic basis of PROs are emerg-
ing. Studies of twins have indicated that heritability esti-
mates for QOL-related domains such as mood and self-
reported health range from 20 to 50% [22–24]. This level
of heritability is comparable or even higher than that of
most diseases. For example, the heritability among the
general population is 42% for prostate cancer, 35% for
colorectal cancer, and 27% for breast cancer. Smaller
percentages of heritability were found for cancer of the
stomach, lung, pancreas, ovary, and bladder [25]. Biolog-
ical pathways have been associated with PROs such as
pain, fatigue, mood, and overall well-being. As a note of
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caution, we would like to highlight that despite high levels
of heritability and known biological pathways, the search
for the myriad of genes and gene interactions involved in
QOL is far from straightforward. Nevertheless, a number of
genes related to these pathways have been identified. The
linkage between patient-reported QOL and genetic vari-
ables has begun to be explored and yields promising results.
Sloan and Zhao [26] were the first to examine the direct link
between polymorphisms and cancer patients’ QOL, using a
large randomized North Central Cancer Treatment Group
clinical trial. More than triple the number of relationships
between genetic variables and patient-reported QOL out-
comes were observed than would be expected by chance
alone. They found evidence for relationships between
overall QOL, symptom distress, and fatigue with variant
genotypes of three enzymes involved in folate metabolism.
Recently, Yang et al. [27] evaluated the role of glutathione-
related genotypes on QOL in advanced non-small cell lung
cancer patients who participated in a clinical trial. Patients
carrying the glutathione peroxidase 1 (GPX1-CC) genotype
had a clinically significant decline in overall QOL, and
physical, functional, and emotional well-being. Clearly,
these findings need to be replicated in future independent
samples. However, the findings are sufficiently compelling
to justify further studies to delineate the genes that are
involved in patient-reported QOL and the extent to which
they impact such PROs.
Clinical implications
The actual translation of genetic knowledge into clinical
practice is one of the key challenges for the next decades
[28, 29]. Genetic factors can be influenced by complex
interactions with other genes, disease processes, and
environmental factors that may change over time, making
it difficult to know how to translate knowledge of these
processes into clinical practice. Moreover, practical appli-
cations need to take issues of validity of the complex
measurements into account [29].
Our vision for the future is nonetheless that emerging
insight into the genetic basis of patient-reported QOL
domains will ultimately allow us to explore new pathways
for improving patient care. Knowledge of the biological
pathways through which various genetic predispositions
propel people toward negative or away from positive health
experiences will ultimately transform health care. If we can
identify patients who are susceptible to poor QOL, we will
be able to better target preventive strategies and/or specific
support, such as interventions inducing lifestyle and
behavioural changes, psychological counseling or therapy,
and/or pharmacological treatment. Such early interventions
may have a profound impact enabling people to experience
substantially greater well-being because they involve the
underlying genetic biology of health (see Theoretical
Underpinnings). Results of this work will thus enable
health care providers to screen for patients who are likely
to experience symptoms and QOL deficits from disease and
its treatments. We hope that as a consequence, clinicians
will be able to intervene prophylactically, monitor patient
well-being, improve treatment decision-making, and
improve outcomes encompassing survival, QOL, and sat-
isfaction with care. Ultimately, QOL can then become an
integral component in the genetic profile. To cite Sloan and
Zhao [26], ‘‘Doctors will eventually use genetic patterns
for several tasks: to tell whether a cancer will spread, to
predict how various therapies such as specific drugs or
radiation will work, and perhaps even to see how some-
one’s QOL will be affected.’’
Theoretical underpinnings
The analysis of the genetic disposition of patient-reported
QOL requires a model to delineate the hypothetical rela-
tionships among QOL domains, biological mechanisms,
and genetic variants. Such a model would need to go
beyond the evident relationships among biological factors
and disease-related symptoms, to acknowledge that QOL
also comprises overall physical, social, and psychological
well-being. We have adopted the widely used theoretical
model of Wilson and Cleary [30] that links biological
factors and patient-reported QOL. We propose a number of
refinements of this model by first including the genetic
underpinnings of biological/physiological variables as well
as of individual characteristics (see Fig. 1). The refinement
also proposes a mutual influence between individual
characteristics and genetic and biological factors, respec-
tively. Additionally, the model allows for interactions to
occur between environment and genetic/biological factors
(e.g., epigenetic mechanisms). Further, the model refine-
ment involves temporal relationships that may change over
time, rendering the model explicitly dynamic. These and
other refinements are described in more detail below. But
first we will present the original model.
The model proposed by Wilson and Cleary [30]
describes a continuum of interrelated levels/measures of
health that can be ordered from more biological (left) to
more psychological complexity and integration (right).
Biological and physiological factors are related to the
function of cells (e.g., creatinine levels), organs (e.g.,
pulmonary wheezes), and organ systems (e.g., the diag-
nosis of colorectal cancer). When the focus is shifted from
cells or specific organ systems to the person as a whole, the
first level encountered is symptom status. This category
was defined as ‘‘the patient’s perception of an abnormal
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physical, emotional, or cognitive state’’ [30; page 61], e.g.,
knee pain or worry. Functional status comprises physical,
social, role, and psychological behavior and is related to
the ability to perform particular defined tasks, e.g., ability
to walk up stairs or handling stressful situations. General
health perceptions refer to subjective evaluations of
physical as well as mental health. Overall quality of life
pertains to subjective assessments of how happy or satisfied
the individual is with his/her life in the context of a specific
physiological state, symptom experience, functional status,
and subjective state of physical and mental well-being.
The arrows in the model indicate causal relationships,
such that biological and physiological variables affect
symptom status, which in turn impacts functional status and
so on. Additionally, characteristics of the individual and of
the environment also exert an impact on the different health
outcomes. The more one moves to the right, the larger this
impact becomes. Wilson and Cleary [30] also pointed out
that the arrows in the model depict the dominant associa-
tions, but that many reciprocal and other relationships exist.
We propose the following extensions of this model to
accommodate emerging evidence of the genetic underpin-
ning of QOL. First, whereas the level of molecular and
genetic factors was implicit in the original model, we
included it as a separate category at the far left. Wilson and
Cleary [30; page 60] acknowledged that the most funda-
mental biological determinants of patient-reported QOL
are molecular and genetic factors. However, these factors
were not incorporated explicitly in their model because
in 1995 (date of publication), these factors were not
commonly measured and applied in routine clinical prac-
tice. The current abundance of genetic research addressing
biological causes and courses of disease warrants this
separate category in the model. These molecular and
genetic factors thus impact symptom status, functional
status, general health perceptions, and overall QOL indi-
rectly via their involvement in the underlying disease.
Second, at the time Wilson and Cleary [30] published
their model, the idea of a relationship between genes and
QOL was far from evident. For example, the notion that
QOL would be genetically determined had not appeared in
the medical literature. Currently, there is mounting evidence
that genes impact the experience of symptoms, perceptions
of health, mood, and QOL in general. Therefore, we have
also incorporated molecular and genetic factors as a separate
category impacting characteristics of the individual. It fol-
lows that these genetic factors impact symptom status,
functional status, general health perceptions, and overall
QOL, via individual characteristics. These sets of genes
may, in part, be the same genes involved in the underlying
condition or disease process. For example, genes involved in
the etiology or biology of pain may be similar to those
involved in the subjective experience of pain. Other genes
may be involved as well, particularly those that impact
individual appraisals and experiences of health and life, e.g.,
via perception, personality, mood, and outlook on life.
Third, Wilson and Cleary [30] built their framework
around dominant unidirectional relationships. We propose
to add bidirectional arrows from characteristics of the
individual to molecular and genetic factors, and biological
Fig. 1 Extended model of
Wilson and Cleary [29].
Interrupted arrows and words in
italics are added to the original
model. Bold arrows were
original in standard font and
highlight the increasingly
acknowledged importance of
the relationships they depict
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and physiological variables, respectively. Clearly, our
genetic and biological makeup has repeatedly been found to
shape the way we are. In other words, the upward arrows are
empirically warranted and beyond dispute. For a long time,
clinicians have been convinced of the reverse impact of our
minds on our body. A well-studied example is pain. There is
emerging evidence that the expectation of clinical benefit is
a major trigger for the placebo effect. Applied to pain, the
expectation of pain relief in response to placebo analgesia
may activate the reward circuitry and the release of dopa-
mine in the ventral striatum, which in turn may trigger the
endogenous opioid system [31]. A maladaptive cognitive
and emotional response to pain is catastrophizing, which
involves feelings of helplessness, rumination, and aggran-
dizing pain-related complaints. Catastrophizing has been
found to be consistently associated with elevated experi-
ences of pain, probably via its effects on the central nervous,
neuromuscular, cardiovascular, immune, and neuroendo-
crine systems [32]. Although evidence of the impact of
cognitive processes and psychological reactions on bodily
processes at the molecular level is emerging, it has yet to be
scientifically articulated. We included this relationship in
the model to indicate that it is an intriguing new frontier. In
the not too distant future, we will no doubt know whether
this bidirectionality is empirically warranted.
Fourth, we added unidirectional arrows from environ-
ment to molecular and genetic factors and biological and
physiological variables. There is emerging evidence that
the environment can alter gene expression, by down- or up-
regulation of the synthesis of specific proteins that affect an
individual’s mental state, by epigenetic mechanisms. For
example, research in rodents indicated that parental nur-
turing behavior can bolster emotional resilience in the
recipient by boosting the expression of the gene that
modulates anxiety. Conversely, distressing events can turn
off the expression of a neuronal growth protein, thereby
eliciting depression [33].
Fifth, we thickened the arrows leading from character-
istics of the individual to symptom status, functional status,
general health perceptions, and overall QOL, as a minor
adaptation. In this way, the increasing evidence is high-
lighted that individual characteristics, such as personality,
illness perceptions, expectations, values, and coping strat-
egies, can exert larger effects on PROs than biological and
physiological variables, such as the underlying disease.
The added arrows to the Wilson and Cleary [30] model
signify the intricate interplay between individual, biologi-
cal, and environmental characteristics at the most funda-
mental level. It should be noted that the current model is a
necessary simplification as multiple determinants interact
and operate in nested genetic, biological, behavioural, and
environmental contexts that change as a person develops.
Thus, the temporal relationships, while not explicitly
addressed in the Wilson and Cleary model, may have a
profound impact on each outcome [34]. Iterative interac-
tions may occur over time (not depicted in the figure). For
example, our genetic make up will influence our individual
characteristics, such as personality and generalized ten-
dencies to appraise experience (e.g., optimistic versus ca-
tastrophizing). This in turn will not only affect our overall
psychological well-being but also our health and symptom
experience, by shaping and perhaps transforming the
underlying biological substrate. This in turn may affect an
individual’s psychosocial environment, and so on.
The suggested modifications cause the model to become
symmetrical. Although it may be a mere graphical artifact,
it is appealing because the gestalt it displays highlights the
interplay between body and mind, or perhaps better,
between brain and mind. It also demonstrates that QOL is
not separate from biological factors. Rather, it represents
the integration of all the preceding factors, including
genetic, physiological, perceptual, and behavioral.
Overview of papers
The aim of the current series of papers is to highlight that
the time has come to investigate the genetic basis of
patient-reported QOL and to stimulate investigations into
the novel and intriguing questions surrounding the genetic
disposition of QOL. In recognition of the magnitude of this
task, we have taken a first step in answering this call to
action by establishing the GENEQOL Consortium.
In pursuing the delineation of the relationship between
genes and QOL, both genetic and QOL research is hindered
by a mono-disciplinary approach. Few genetic researchers
use QOL endpoints, and similarly few QOL researchers are
engaged in genetic research. Therefore, it is of paramount
importance to join forces among the disparate disciplines.
This primary aim of the international and interdisciplinary
GENEQOL Consortium is to provide the requisite foun-
dation and research culture to stimulate the development of
this multi-disciplinary field of research. We started to
identify five primary patient-reported QOL outcomes as
initial targets: self-rated physical health, pain, fatigue,
negative psychological affect, and positive psychological
affect. The first tangible objective of the GENEQOL
Consortium was to develop a list of potential biological
pathways, genes, and genetic variants involved in these
QOL outcomes, by reviewing genetic studies. The estab-
lishment of the Consortium and its first results has been
described in an omnibus paper [35].
This special series of papers informs readers of Quality
of Life Research about this groundbreaking and emerging
area of research and provides a more detailed summary of
its first results than was possible in the context of the
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omnibus paper. The series covers both the advances in
genetic and patient-reported QOL research that allow for
further investigation of the genetic underpinnings of such
PROs, but also articulates outstanding questions. It starts
with the current paper and is followed by a reflection from
a patient perspective by Chauhan [36]. She emphasizes that
researchers interested in the genetic disposition of QOL
share with patients complementary goals on the journey to
enhance patients’ QOL. By developing scientific validation
for patient-reported experiences, researchers help the cli-
nicians to focus more on the patients’ perceptions. Identi-
fication of the genetic components validates the reality of
the patient experience and makes clinicians more amenable
to that reality as an important component of disease pro-
gression and treatment plans.
Shi and colleagues [37] address pain and provide an
overview of the current knowledge of pain- and analgesic-
related pathways, genes, and genetic variants. The authors
describe three categories of potential genetic pathways for
pain perception. They also present the genes related to
pharmacodynamics (receptor interactions, intracellular sig-
naling, and modulation of opioid effects) and pharmacoki-
netics (metabolism and transport) of responses to analgesics.
The paper by Barsevick and colleagues [38] addresses
the biological and genetic mechanisms of cancer-related
fatigue. This significant symptom affects over 60% of
cancer patients. The authors first describe a number of
pathophysiological pathways that are hypothesized to be
involved in fatigue, including, cytokine dysregulation,
hypothalamic-pituitary-adrenal axis dysfunction, neuro-
transmitter dysregulation, and disruption of the circadian
rhythm. The authors also address current evidence for the
genetic control of cancer-related fatigue. For example, a
number of cytokine genes and their polymorphisms have
been proposed as candidate markers for the study of can-
cer-related fatigue. The identification of these pathways
and genetic control mechanisms hold promise for the
identification of effective treatments.
The paper by Sprangers and colleagues [39] focus on
individuals’ emotional states. These authors provide a
summary of the heritability studies on negative as well as
positive emotional states and show that heritability esti-
mates for anxiety and depression (30%–40%) are slightly
lower than those for positive emotional states (40%–50%).
Additionally, biological pathways and genetic variants are
described that are involved in these affect states. The
hypothalamo-pituitary-adrenal axis was found to be a
central system in the etiology of depression. Biological and
genetic backgrounds of positive emotional states were
found to be rarely investigated.
The work by the GENEQOL Consortium is expanded to
include the investigation of relationships between genetic
variables and QOL of over 8,000 mothers and pregnant
women and near to 6,000 of their young children [40].
QOL of mothers and children was measured longitudinally
and DNA was extracted. Candidate genes have been
studied and GWAS of QOL of both mothers and young
children will be performed. This study is an example of a
large birth cohort study that is one of the first to provide
insight into the genetic underpinning of QOL of mothers
and their young children. Moreover, the authors provide a
template for data analyses to stimulate further research.
Parting thoughts: the path forward
The major aim of this series of publications is to stimulate
researchers in the fields of genetics and patient-reported
QOL to become engaged in this broad-ranging scientific
endeavor. We are well aware that the combination of two
scientific fields does not only bring together formidable
scientific expertise but also compounds the scientific chal-
lenges inherent to each field. We hope that this series of
papers will provide a path for QOL and genetics researchers
to join forces to move this field forward in tangible ways and
to unravel the intricate interplay of the genetic underpin-
nings of patient-reported QOL outcomes. The ultimate result
will be a better understanding of the process relating disease,
patient, and doctor that will have the potential to lead to
improved survival, QOL, and health services delivery.
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Appendix A: Glossary
Chromosome: Self-replicating structures in the nucleus
of a cell that carry the genetic information [41].
DNA (deoxyribonucleic acid): The double-stranded
molecule that encodes genetic information [42].
Epigenetics: The study of heritable changes to DNA
structure that do not alter the underlying sequence [43].
Gene: The basic unit of inheritance. A sequence of DNA
that codes for a particular protein product [42].
Genome: The entire collection of genetic information (or
genes) that an organism possesses [41].
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Genome-wide association study (GWAS): A study that
evaluates association of genetic variation with outcomes
or traits of interest by using 100,000–1,000,000 markers
or more across the genome [41].
Genotype: The genetic constitution of an individual [41].
Heritability: The proportion of phenotypic differences
among individuals that can be attributed to genetic
differences in a particular population [42].
High-throughput sequencing: High-speed and low-cost
DNA sequencing.
Locus (plural, loci): The site(s) on a chromosome at
which the gene for a particular trait is located [41].
Phenotype: An observed characteristic of an individual
that results from the combined effects of genotype and
environment [42].
Polymorphism: The existence of two or more variants of
a gene, occurring in a population, with at least 1%
frequency of the less common variant (cf mutation) [41].
Twin study: Study comparing the resemblance of iden-
tical and fraternal twins to estimate genetic and
environmental components of variance [42].
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